News summary

Cognito’s Alzheimer’s device shows promise in mild disease

Source: Longevity Technology • Published: 19 Nov 2026, 12:51

Summarized by Masters of Longevity from Longevity Technology.

Noninvasive neuromodulation showed clinical benefit signals in mild Alzheimer’s.

Cognito’s Alzheimer’s device shows promise in mild disease
Key Takeaways
  • HOPE reported positive clinical signals in mild Alzheimer’s.
  • A noninvasive neuromodulation device was tested in patients.
  • Results were presented at the Clinical Trials on Alzheimer’s conference.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.MoL PickSeed Oils and Health: Inflammation, Processing and EvidenceHuman trials, processing risks and long-term health ask different questions. What can seed-oil research tell us—and what remains unresolved?